Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Albumin Paclitaxel vs FLOT in Neoadjuvant Gastric Cancer
NCT05610332Phase 3Not yet recruiting
- Sponsor
- Fujian Medical University
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of camrelizumab in gastric cancer (GC), sponsored by Fujian Medical University. Primary endpoint: Objective Response Rate at 4 months. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05610332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05610332.